Richard Rosse is a Psychiatry physician. OpenAlex indexes 171 publications with 3,832 citations (h-index 35).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
420 S Main St Ste A
Emporia, VA 238470016
Telephone
434-201-2025Provider last certified this registry record 28 May 2025.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
94.4%Atypical Antipsychotic32.7%Risperidone19%Quetiapine Fumarate18%Aripiprazole14%Olanzapine13%Latuda13%Quetiapine Fumarate Er8%Invega Sustenna6%Abilify Maintena5%Risperidone Odt3%Ziprasidone Hcl3%Part D<11 patientsSSRI15.9%Fluoxetine Hcl23%Escitalopram Oxalate22%Trazodone Hcl21%Citalopram Hbr17%Sertraline Hcl9%Paroxetine Hcl5%Fluvoxamine Maleate4%Part D<11 patients+ 12 more classes in this area
Cardiovascular
3.3%Central alpha-2 Adrenergic Agonist2.4%Clonidine Hcl100%Part D<11 patientsBeta blocker0.9%Metoprolol Tartrate100%Part D<11 patientsHormonal (systemic)
1.7%l-Thyroxine0.9%Levothyroxine Sodium100%Part D<11 patientsl-Triiodothyronine0.8%Liothyronine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy
Schizophrenia Research
2013 - Valproate-Induced Hyperammonemic Encephalopathy and Normal Liver Functions
Clinical Neuropharmacology
2009 - Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders
Clinical Neuropharmacology
2008 - First Administration of Cytidine Diphosphocholine and Galantamine in Schizophrenia
Clinical Neuropharmacology
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”